CY1106892T1 - Νεα μεθοδος θεραπειας - Google Patents

Νεα μεθοδος θεραπειας

Info

Publication number
CY1106892T1
CY1106892T1 CY20071101240T CY071101240T CY1106892T1 CY 1106892 T1 CY1106892 T1 CY 1106892T1 CY 20071101240 T CY20071101240 T CY 20071101240T CY 071101240 T CY071101240 T CY 071101240T CY 1106892 T1 CY1106892 T1 CY 1106892T1
Authority
CY
Cyprus
Prior art keywords
insulin sensitizer
diabetes mellitus
treatment
plasma
effective
Prior art date
Application number
CY20071101240T
Other languages
English (en)
Inventor
Lisa Benincosa
William Jusko
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106892(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of CY1106892T1 publication Critical patent/CY1106892T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Μια μέθοδος για την θεραπεία του τύπου 2 σακχαρώδη διαβήτη και των παθήσεων που συνδέονται με το σακχαρώδη διαβήτη, η οποία μέθοδος περιλαμβάνει τη χορήγηση σε ένα άνθρωπο ή μη-ανθρώπινο θηλαστικό σε ανάγκη της, μιας αποτελεσματικής μη τοξικής ποσότητας ενός ευαισθητοποιητή ινσουλίνης ώστε να παρασχεθεί μια συγκέντρωση πλάσματος του ευαισθητοποιητή ινσουλίνης τουλάχιστον ενός οριακού επιπέδου (η "οριακή συγκέντρωση πλάσματος") από μέσα από τη κλίμακα των αποτελεσματικών επιπέδων πλάσματος του ευαισθητοποιητή ινσουλίνης, συνθέσεις για χρήση σε τέτοια μέθοδο και μεθοδολογία για τον καθορισμό των συγκεντρώσεων πλάσματος του δραστικού παράγοντα χρησιμοποιούμενου σε τέτοιες μεθόδους.
CY20071101240T 1998-11-12 2007-09-27 Νεα μεθοδος θεραπειας CY1106892T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824893.3A GB9824893D0 (en) 1998-11-12 1998-11-12 Novel method of treatment
PCT/US1999/026746 WO2000027341A2 (en) 1998-11-12 1999-11-12 Novel method of treatment

Publications (1)

Publication Number Publication Date
CY1106892T1 true CY1106892T1 (el) 2012-01-25

Family

ID=10842389

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101240T CY1106892T1 (el) 1998-11-12 2007-09-27 Νεα μεθοδος θεραπειας

Country Status (40)

Country Link
EP (2) EP1759698A1 (el)
JP (1) JP2003521455A (el)
KR (2) KR20010080440A (el)
CN (3) CN101244062A (el)
AP (2) AP2005003432A0 (el)
AR (2) AR029149A1 (el)
AT (1) ATE366573T1 (el)
AU (1) AU768303B2 (el)
BG (2) BG65577B1 (el)
BR (1) BR9915284A (el)
CA (1) CA2350425C (el)
CO (1) CO5150158A1 (el)
CY (1) CY1106892T1 (el)
CZ (1) CZ299801B6 (el)
DE (1) DE69936533T2 (el)
DK (1) DK1135128T3 (el)
DZ (1) DZ2938A1 (el)
EA (2) EA009192B1 (el)
ES (1) ES2289833T3 (el)
GB (1) GB9824893D0 (el)
HK (1) HK1041202B (el)
HR (1) HRP20010344B1 (el)
HU (1) HUP0104262A3 (el)
IL (1) IL143088A0 (el)
MA (1) MA26759A1 (el)
MY (1) MY128347A (el)
NO (1) NO328391B1 (el)
NZ (1) NZ527132A (el)
OA (1) OA12193A (el)
PE (1) PE20001239A1 (el)
PL (1) PL349421A1 (el)
PT (1) PT1135128E (el)
RS (1) RS50130B (el)
SK (1) SK286357B6 (el)
TR (1) TR200101348T2 (el)
TW (1) TWI234456B (el)
UA (1) UA79730C2 (el)
UY (2) UY25797A1 (el)
WO (1) WO2000027341A2 (el)
ZA (1) ZA200103793B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
JP2005514399A (ja) * 2001-12-21 2005-05-19 スミスクライン ビーチャム コーポレーション ＰＰＡＲγアクチベーターの投薬法
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469331A (ja) * 1990-07-10 1992-03-04 Asahi Chem Ind Co Ltd 徐放性エマルジョン製剤
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478853A (en) * 1992-10-12 1995-12-26 Adir Et Compagnie Thazolidinedione compounds
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
CA2115587A1 (en) * 1993-02-18 1994-08-19 Hayato Kihara Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes

Also Published As

Publication number Publication date
UY25801A1 (es) 2000-08-21
GB9824893D0 (en) 1999-01-06
BG110061A (bg) 2008-12-30
PL349421A1 (en) 2002-07-29
ATE366573T1 (de) 2007-08-15
AU1719600A (en) 2000-05-29
OA12193A (en) 2006-05-09
DE69936533D1 (de) 2007-08-23
CZ20011656A3 (cs) 2002-06-12
DE69936533T2 (de) 2008-03-13
HK1041202A1 (en) 2002-07-05
BR9915284A (pt) 2002-02-13
CN1354661A (zh) 2002-06-19
CN101244062A (zh) 2008-08-20
EA009192B1 (ru) 2007-12-28
IL143088A0 (en) 2002-11-10
CA2350425A1 (en) 2000-05-18
BG65577B1 (bg) 2009-01-30
TR200101348T2 (tr) 2002-02-21
DZ2938A1 (fr) 2004-03-15
RS50130B (sr) 2009-03-25
MA26759A1 (fr) 2004-12-20
CO5150158A1 (es) 2002-04-29
HUP0104262A3 (en) 2003-06-30
NZ527132A (en) 2005-01-28
NO328391B1 (no) 2010-02-08
AU768303B2 (en) 2003-12-04
WO2000027341A2 (en) 2000-05-18
KR20010080440A (ko) 2001-08-22
CZ299801B6 (cs) 2008-11-26
BG105569A (en) 2002-01-31
HRP20010344B1 (en) 2008-02-29
EP1135128A4 (en) 2003-07-16
HUP0104262A2 (en) 2002-08-28
KR20070048279A (ko) 2007-05-08
EP1135128B1 (en) 2007-07-11
HRP20010344A2 (en) 2002-06-30
TWI234456B (en) 2005-06-21
AP2005003432A0 (en) 2005-12-31
CN1771943A (zh) 2006-05-17
JP2003521455A (ja) 2003-07-15
EA200700968A1 (ru) 2008-06-30
AR029149A1 (es) 2003-06-18
SK6422001A3 (en) 2001-12-03
PT1135128E (pt) 2007-10-12
AP1580A (en) 2006-02-24
EP1135128A2 (en) 2001-09-26
NO20012301D0 (no) 2001-05-10
WO2000027341A3 (en) 2000-09-08
EP1759698A1 (en) 2007-03-07
MY128347A (en) 2007-01-31
DK1135128T3 (da) 2007-11-05
EA200100539A1 (ru) 2001-12-24
PE20001239A1 (es) 2000-12-24
ES2289833T3 (es) 2008-02-01
CN1235586C (zh) 2006-01-11
ZA200103793B (en) 2002-06-05
YU37401A (sh) 2005-07-19
UY25797A1 (es) 2000-12-29
AR029317A1 (es) 2003-06-25
UA79730C2 (en) 2007-07-25
SK286357B6 (sk) 2008-08-05
HK1041202B (zh) 2007-10-05
CA2350425C (en) 2009-06-02
NO20012301L (no) 2001-07-09

Similar Documents

Publication Publication Date Title
NO20020056D0 (no) Fremgangsmåte og system for anvendelse ved behandling av en pasient med et hvilket som helst medikament for å optimalisereterapien og forhindre en negativ medikamentrespons
ATE327764T1 (de) Hmg1 antagonisten zur behandlung von entzündungen
ATE511655T1 (de) Verfahren zur auswertung eines myelounterdrückungszustands
NO976063L (no) Fremgangsmåte for behandling av diabetes
DK1243278T3 (da) Anvendelse af blod, som har en foröget koncentration af nitrogenoxid, til fremstilling af et medikament
LU91926I2 (fr) Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®)
PE20030400A1 (es) Productos en gel para la axila con componentes de bloque de agua
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
DK1301201T3 (da) Behandling af glycogenosis type II
ATE526029T1 (de) Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
BR0009776A (pt) Método de tratamento
EA200100571A1 (ru) Комбинированный способ лечебного воздействия, включающий применение лучевой терапии и ингибитора циклооксигеназы-2(cox-2) для лечения неоплазии
ID30237A (id) KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
ATE358474T1 (de) Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung
CY1106892T1 (el) Νεα μεθοδος θεραπειας
TR200100974T2 (tr) Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi
TR200201150T2 (tr) Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod.
DE69916643D1 (de) Verwendung von hyaluronsäure zur behandlung der bestrahlungs-blasenentzündung
ATE526992T1 (de) Methode zum schutz therapeutischer zusammensetzungen von hostvermittelter inaktivierung
Cao et al. NK2 receptor-mediated spontaneous phasic contractions in normal and ulcerative colitis human sigmoid colon
BR0307882A (pt) Métodos para detectar a presença de um agente adventìcio em uma composição compreendendo um reovìrus e um vìrus, e para validar uma composição compreendendo um microorganismo, e, célula indicadora útil para detectar um agente adventìcio em uma composição de microorganismo
ECSP993217A (es) Nuevo metodo tratamiento vii
ATE449866T1 (de) Verfahren zum evaluieren antifungaler agensien
NO982854D0 (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина